UNSPSC 51384626: Lonazolac calcium

This classification denotes a nonsteroidal antiinflammatory drug 2C17H12ClN2O2.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0H73O2AC36, chemically known as 1h-pyrazole-4-acetic acid, 3-(4-chlorophenyl)-1-phenyl-, calcium salt, but more generally known as lonazolac calcium, which bears US NIH Compound Identifier 156369. European Medicines Agency schedules Lonazolac calcium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02968MIG.

Most nations, for tariff and trade purposes, schedule lonazolac calcium under HS 29331990 and SITC 51571. As of Q4 2014, LONAZOLAC CALCIUM remains US FDA's Preferred Term for this commodity. SMILES: C1CCC(CC1)N2CC(C(N2)C3CCC(CC3)CL)CC(=O)[O-].C1CCC(CC1)N2CC(C(N2)C3CCC(CC3)CL)CC(=O)[O-].[CA+2].

UNSPSC 51384626 Lonazolac calcium, a Commodity code, does not map to the recent state and local procurement activity tagged under it. The single recent opportunity on file—Seminole County, Florida's IFB60459723LAS—solicits Naloxone and Safe Drug Deactivation Systems, neither of which falls under lonazolac calcium, an anti-inflammatory pharmaceutical ingredient. The mismatch suggests either a data-entry error in the source or a misalignment between the code assigned and the work actually being purchased. State and local procurement under this specific Commodity code shows no relevant recent activity in the available source material.

No representative opportunities aligned with lonazolac calcium procurement are present in recent state and local solicitation records. A business development professional targeting this code should verify whether state and local buyers actually solicit lonazolac calcium as a standalone line item or whether procurement activity occurs under a different UNSPSC code, a cooperative purchasing vehicle, or a pharmaceutical category with broader scope. The absence of activity on file does not confirm no market exists, but it signals either low procurement volume, consolidation under higher-tier pharmaceutical codes, or procurement channels not captured in this snapshot.